Go to content

Publications

510 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Advice - do not reimburse nivolumab-relatlimab (Opdualag®) for the treatment of skin cancer

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse ...

    Report | 23-05-2024

  2. Advice - conditional inclusion of pembrolizumab (Keytruda®) as an additional treatment of breast cancer prior to surgery

    The National Health Care Institute has advised the Minister for Medical Care to reimburse pembrolizumab (Keytruda®) immunotherapy ...

    Report | 23-05-2024

  3. Progress report on the conditional inclusion of orphan drugs, conditionals and exceptionals (progress report year 2023)

    At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute publishes an annual report ...

    Report | 23-05-2024

  4. Advice - reimburse relugolix (Orgovyx®) for the treatment of prostate cancer

    The National Health Care Institute has advised the Minister for Medical Care to reimburse relugolix (Orgovyx®) from the basic ...

    Report | 21-05-2024

  5. Advice - Reimburse codeine only for the treatment of severe, chronic diarrhoea

    The National Health Care Institute has advised the Minister for Medical Care to reimburse codeine only for the treatment of ...

    Report | 15-05-2024

  6. Advice - reimburse selumetinib (Koselugo®) for the treatment of benign tumours in children with neurofibromatosis type 1 (NF1)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse selumetinib ...

    Report | 25-04-2024

  7. Advice - Reimburse lisocabtagene maraleucel (Breyanzi®) for the treatment of lymphoma

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse lisocabtagene ...

    Report | 11-04-2024

  8. Advice - Reimburse deucravacitinib (Sotyktu®) for the treatment of moderate-to-severe psoriasis

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse deucravacitinib ...

    Report | 27-03-2024

  9. Advice - reimburse keto- and hydroxyanalogues (Ketosteril®) for the treatment of severe kidney disease

    The National Health Care Institute has advised the Minister for Medical Care to reimburse keto- and hydroxyanalogues ...

    Report | 25-03-2024

  10. Advice - Reimburse bulevirtide (Hepcludex®) for the treatment of chronic hepatitis delta virus (HDV) infection in certain patients

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse bulevirtide ...

    Report | 13-03-2024

Go to